Evidence map›Paper›PMID 36344243›Full record

ArticleTechnology in cancer research & treatment

Sequential Administrations of a Vascular-Disrupting Agent, High-Intensity Focused Ultrasound, and a Radioactively labeled Necrosis Avid Compound for Eradicating Solid Malignancies.

Yue Li, Shuncong Wang, Lei Chen, Yuanbo Feng, Zhijun Shen, Xin Chen, Gang Huang, Yicheng Ni

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yue LiShanghai Key Laboratory of Molecular Imaging, 74753Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, China.ORCID 0000-0002-4703-1651
Shuncong WangDepartment of Imaging & Pathology, 71510Biomedical Sciences Group, KU Leuven, Leuven, Flanders, Belgium.
Lei ChenDepartment of Imaging & Pathology, 71510Biomedical Sciences Group, KU Leuven, Leuven, Flanders, Belgium.
Yuanbo FengDepartment of Imaging & Pathology, 71510Biomedical Sciences Group, KU Leuven, Leuven, Flanders, Belgium.
Zhijun ShenSchool of Clinical Medicine, 191610Shanghai University of Medicine and Health Sciences, Shanghai, China.
Xin ChenCollege of Public Health, 191610Shanghai University of Medicine and Health Sciences, Shanghai, China.
Gang HuangShanghai Key Laboratory of Molecular Imaging, 74753Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, China.
Yicheng NiDepartment of Imaging & Pathology, 71510Biomedical Sciences Group, KU Leuven, Leuven, Flanders, Belgium.
KU Leuven · BEJiading District Central Hospital · CNShanghai University of Medicine and Health Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radical treatment of malignant solid tumors should aim to be less traumatic, precise, and effective. OncoCiDia, as a noninvasive, sequential dual-targeting, small-molecule, broad spectrum anticancer theranostic approach, may fulfill these requirements of solid cancer (Onco) treatment with both tumoricidal (Ci) and diagnostic (Dia) effects. However, it is unlikely to cure patients with cancer, especially those with large and irregular tumors and with tumors residing in certain organs, such as the brain and pancreas, because of insufficient necrosis generation. To amplify ablative efficacy, this shortcoming could be overcome by combining high-intensity focused ultrasound (HIFU) with the use of a vascular-disrupting agent (VDA) and a radioactively labeled necrosis avid compound (NAC), such as

Indexed as

High-Intensity Focused Ultrasound AblationNeoplasmsHumansIodine RadioisotopesNecrosisIodine-131Iodine Radioisotopesbroad spectrum anticancerHIFUhypericininternal radiationOncoCiDiatargeted therapyvascular-disrupting agent

Identifiers

PMID36344243
PMCPMC9647265
OpenAlexW4308635024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.